EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial

Kexiang Yan, Fuqiu Li, Xiaodong Bi, Ling Han, Zhenghua Zhang, Rixin Chen, Yuye Li, Litao Zhang, Xiaohua Wang, Linfeng Li, Jianyun Lu, Ai'e Xu und 26 weitere

Journal of the American Academy of Dermatology · 2025-01 · 92 (1) · 92-99

DOI: 10.1016/j.jaad.2024.09.031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025-01. Verfasst von Kexiang Yan und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, Severity of Illness Index, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Jiangsu Hengrui Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vunakizumab, a novel anti-interleukin-17A antibody, has shown promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial. OBJECTIVE: We conducted a double-blind, randomized phase 3 trial (NCT04839016) to further evaluate vunakizumab in this population. METHODS: Six hundred ninety subjects were randomized (2:1) to receive vunakizumab 240 mg or placebo at weeks 0, 2, 4, and 8. At week 12, subjects on placebo were switched to vunakizumab 240 mg (weeks 12, 14, 16, and every 4 weeks thereafter). The co-primary endpoints were ≥90% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 90) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12. RESULTS: At week 12, the vunakizumab group showed higher PASI 90 (76.8% vs 0.9%) and sPGA 0/1 (71.8% vs 0.4%) response rates, as well as higher PASI 75 (93.6% vs 4.0%), PASI 100 (36.6% vs 0.0%), and sPGA 0 (38.2% vs 0.0%) response rates (all two-sided P < .0001 vs placebo). Efficacy was maintained through week 52 with continuous vunakizumab. Possible treatment-related serious adverse events occurred in 0.9% of vunakizumab-treated subjects. LIMITATIONS: Chinese subjects only; no active comparator. CONCLUSION: Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisSeverity of Illness IndexAntibodies, Monoclonal, HumanizedHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultTreatment OutcomeChronic DiseaseInterleukin-17

Stichwörter der Autor:innen

Psoriasis Area and Severity Indexanti-IL-17Abiologicsclinical trialplaque psoriasisquality of life

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-17

Autor:innen und Institutionen

  • Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
  • Department of Dermatology, The Second Hospital of Jilin University, Changchun, China.
  • Department of Dermatology, Nanyang First People's Hospital, Nanyang, China.
  • Department of Dermatoloogy, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.

Förderung

  • Jiangsu Hengrui Medicine

Zitieren

APA

Yan, K., Li, F., Bi, X., Han, L., Zhang, Z., Chen, R., Li, Y., Zhang, L., Wang, X., Li, L., Lu, J., Xu, A., Yang, S., Lu, Y., Sun, J., Li, Z., Zhu, X., Jiang, M., Zhang, S., …, & Xu, J. (2025). Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 92(1), 92-99. https://doi.org/10.1016/j.jaad.2024.09.031

Vancouver

Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology. 2025;92(1):92-99. doi:10.1016/j.jaad.2024.09.031

BibTeX
@article{Yan2025,
  author = {Yan, Kexiang and Li, Fuqiu and Bi, Xiaodong and Han, Ling and Zhang, Zhenghua and Chen, Rixin and Li, Yuye and Zhang, Litao and Wang, Xiaohua and Li, Linfeng and Lu, Jianyun and Xu, Ai'e and Yang, Sen and Lu, Yan and Sun, Jianfang and Li, Zhiming and Zhu, Xiaohong and Jiang, Meiying and Zhang, Siping and Wang, Wenqing and Li, Yanling and Meng, Zudong and Li, Hongyi and Mou, Kuanhou and Han, Xiuping and Li, Shanshan and Chen, Aijun and Li, Xin and Liu, Donghua and Zhang, Chunlei and Ji, Chao and Wang, Yu and Cheng, Hao and Cui, Xiaojing and Yao, Xiaoyan and Bai, Xiaoyan and Dong, Guangchao and Xu, Jinhua},
  title = {Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  volume = {92},
  number = {1},
  pages = {92--99},
  doi = {10.1016/j.jaad.2024.09.031}
}
Kostenlos starten →